KemPharm – Collaboration and License Agreement for KP415 and KP484, its ADHD Candidates, May Help Reinvigorate the Company
KemPharm (NASDAQ: KMPH), a specialty pharmaceutical company, has entered into a collaboration and licensing agreement with an affiliate of Gurnet Point Capital (GPC) in exchange for an upfront payment of $10 million, in addition to receiving pre-approval cost reimbursements, regulatory milestone and sales milestone amounting...
